Navigation Links
Pharmaxis Announces New Drug Application Submission for Aridol(TM)
Date:3/1/2009

actitioner (GP). Yet GPs currently rely upon older tests that are often inaccurate and cumbersome to assess airway inflammation in patients with asthma. The easy to administer test uses a patented formulation of mannitol processed into a breathable powder. The test requires the patient to inhale increasing doses of Aridol, which causes the airways to narrow and contract that is simply detected by measuring the amount of air a person can exhale in one second. The smaller the dose required to cause contraction, the more severe the patient's asthma diagnosis. People without airway inflammation do not respond to an Aridol challenge test.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE Pharmaxis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... FORT WORTH, Texas, Dec. 16 ... WNDM) a rapidly growing provider of specialty ... Orthopedics operating subsidiary is moving toward productization ... The company currently anticipates products to ... bio-products market, estimated to be a multi-billion ...
(Date:12/16/2009)... -- A new application developed by American Imaging ... specialty pharmaceuticals has increased health plan staff productivity ... costs. ,, AIM, a leading diagnostic imaging benefit ... representing over 35 million consumers and an operating ... ), adapted the successful clinical and technology platform ...
(Date:12/16/2009)... -- AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" ... closed a bridge loan financing (the "2009 Financing") ... Agreement (the "Agreement") with Firebird Global Master Fund, ... sold a convertible promissory note, due June 30, ... and issued a warrant to purchase an aggregate ...
Breaking Medicine Technology:Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4New combination therapy could deliver powerful punch to breast cancer 61445 1New combination therapy could deliver powerful punch to breast cancer 61445 2Indiana University receives NIH grant to improve health care in East Africa 61442 1Indiana University receives NIH grant to improve health care in East Africa 61442 2Indiana University receives NIH grant to improve health care in East Africa 61442 3Scientists guide immune cells with light and microparticles 10745 1Scientists guide immune cells with light and microparticles 10745 2
... Researchers at Tufts Medical Center have created ... that individuals with certain genetic profiles and lifestyle ... a potentially blinding condition that currently affects an ... dramatically as the population ages. The study, led ...
... yielded nearly double SVR rate compared to standard ... 900518 presented at EASL annual meetingCOPENHAGEN, Denmark, April ... ) today reported that final results of the ... hepatitis C protease inhibitor, in combination with peginterferon ...
Other Medicine Technology:Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD) 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12
(Date:12/17/2009)... radiation doses delivered during computed tomography examinations underscore the ... minimizing dose and protecting patients, according to the American ... ... Albuquerque, NM (Vocus) December 16, 2009 ... computed tomography examinations underscore the important role that competent, ...
(Date:12/17/2009)... Md., Dec. 17 Motionsoft, Inc. announced ... Payment Card Industry (PCI) Data Security Standards (DSS) ... of software vendors in the health and wellness ... The PCI Standard is the result of a ... card companies (Visa International, MasterCard Worldwide, American Express, ...
(Date:12/17/2009)... Virtual Health Technologies, Inc. (OTC Bulletin ... wholly owned operating subsidiary of VHGI) is interviewing ... assist with evaluating potential International Mining Acquisitions. ... the role and hopes to make an announcement ... ventures and opportunities within the overseas Gold and ...
(Date:12/17/2009)... Jerusalem Kuvin Center for the Study of Infectious ... grant from the Bill & Melinda Gates Foundation ... The project will be led by Prof. Alon ... of Medical Research Israel-Canada at the Hebrew University,s ... on the ecology and transmission dynamics of visceral ...
(Date:12/17/2009)... Dec. 17 Stem cells that could one day ... be easily harvested from the tissue of the umbilical ... provides precursor cells to treat some blood disorders, said ... online version of the Journal of ... cells can be expanded to greater number, are remarkably ...
Breaking Medicine News(10 mins):Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4Health News:Motionsoft Completes PCI Compliance Certification 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 3Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 4Health News:Hebrew U. receives $5 million for research on leishmaniasis in Ethiopia 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2
... 29 ConvaTec, a world-leading,developer and marketer of ... announced that Michael E. Steadman will join ConvaTec,as ... and Nino,Pionati has been appointed as President of ... company had announced the formation of four new,operating ...
... is First to Use IPL to Clear Acne ... CLRS Technology today,announced the CLARO acne-clearing device received ... (FDA) for treatment of mild to moderate,inflammatory acne. ... Pulsed,Light (IPL) for treatment of acne, will be ...
... The Melting Pot Restaurants join,St. Jude Children,s Research ... Nov. 1 - Dec. 31 to "give thanks for ... who are not.", "From the beginning, our involvement ... and guests," said Kendra Sartor, vice president,of brand development ...
... today that it has been chosen to present at the 2008 Life Sciences ... City. , ... Rye, NY (PRWEB) October 29, 2008 -- Curemark announced today ... Healthcare Venture Summit October 30, 2008 to be held in New York City., ...
... Global biochips market is forecast to experience robust growth and is ... party reimbursement, and a growing number of individuals suffering from common ... ... San Jose, CA (PRWEB) October 29, 2008 -- Significant dimensions of ...
... temporary tattoos provide peace of mind for caregivers, their children and those ... with non-speaking Autism and Down Syndrome, as well as wandering children - ... returned to the care of those who love them. , ... Boca ...
Other Medicine News:Health News:ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units 2Health News:CLARO Receives FDA-Clearance for Treatment of Acne 2Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 2Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 3Health News:Curemark to Present at the 2008 Life Sciences & Healthcare Venture Summit 2008 2Health News:World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:A Universal Gift of Peace of Mind 2Health News:A Universal Gift of Peace of Mind 3
... the Anterior Segment The BD is optimized ... ophthalmologists specializing in the anterior segment. It is ... c-mount camera on the BD 900- may be ... in 10 and 16 X times- through the ...
... The BP 900 offers ... Designed for routine practice, the ... optical system and progressive functionality. ... for video, one for digital ...
... The NanoChip 400 System is an automated ... for performing SNP detection, pathogen sequence detection ... targets can be applied to an open ... which may be reused until all tests ...
... for venous pressure monitoring, blood sampling, ... Turbo-Flo polyurethane PICC line sets offer:, ... Micropuncture Introducer Needle, Biocompatible ... trimmed to patient specific anatomy. Remove ...
Medicine Products: